A decision made by the U.S. Court of Appeals for the Federal Circuit delivered a blow to Biogen Inc., denying a second look into the patent dispute filed against Mylan Pharmaceuticals Inc.
Thirty five generic drugmakers around the world will make cheap versions of Pfizer Inc.’s highly effective COVID-19 oral antiviral Paxlovid to supply the treatment in 95 poorer countries, the U.N.-backed Medicines Patent Pool (MPP) said on March 17.
Bristol Myers Squibb’s blockbuster cancer drug Revlimid finally has a competitor as Teva Pharmaceuticals announced the launch of a generic version of Revlimid, which could significantly cut into the global biopharmaceutical company’s earnings.
Prices increased on 810 different medications by the end of January 2021, not only on branded medications but also some generic drugs, according to a pricing report from GoodRx Health.
The U.S. health regulator approved the first generic version of AbbVie Inc.’s Restasis, a treatment used in increasing tear production in patients with dry-eye syndrome.
Akhil Ravi appointed CEO of Aurigene Pharmaceutical Services Ltd. Hyderabad, India, February 1, 2022 – Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”) today […]
Vincent Colicchio – Vice President, Supply Chain and External Manufacturing for Dr. Reddy’s Laboratories – discusses supply chain, manufacturing and training issues pertaining to generic drug manufacturing.
Pfizer Inc. said on Tuesday the company will allow generic manufacturers to supply its experimental antiviral Covid-19 pill to 95 low-income and middle-income countries through a licensing agreement with the international public health group Medicines Patent Pool (MPP).
Merck & Co. signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of the company’s experimental oral antiviral Covid-19 treatment, the U.S. drugmaker and the organization announced on Oct. 27.
With companies like GlaxoSmithKline and bluebird bio moving closer to splitting their businesses into multiple entities, Novartis is reviewing the Swiss drugmaker’s Sandoz division to determine the best moves going forward to maximize value for shareholders.
